Arun Das Net Worth

What's Arun Das's mailing address?

Arun's mailing address filed with the SEC is C/O CABALETTA BIO, INC., 2929 ARCH STREET, SUITE 600, PHILADELPHIA, PA, 19104.

Insiders trading at Cabaletta Bio Inc

Over the last 5 years, insiders at Cabaletta Bio Inc have traded over $19,324,000 worth of Cabaletta Bio Inc stock and bought 1,500,545 units worth $13,043,398 . The most active insiders traders include Group, Llc Green Jeremy Red..., Ventures V, L.P.5 Am Opport... et James E Deerfield Mgmt Iv, .... On average, Cabaletta Bio Inc executives and independent directors trade stock every 70 days with the average trade being worth of $632,329. The most recent stock trade was executed by Gwendolyn Binder on 19 January 2024, trading 11,000 units of CABA stock currently worth $11,110.

What does Cabaletta Bio Inc do?

cabaletta bio, inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered t cell therapies for patients with b cell-mediated autoimmune diseases. its proprietary technology utilizes chimeric autoantibody receptor (caar) t cells that are designed to selectively bind and eliminate b cells, which produce disease-causing autoantibodies or pathogenic b cells. the company's lead product candidate is dsg3-caart, which is in phase i clinical trial for the treatment of mucosal pemphigus vulgaris, an autoimmune blistering skin disease, and hemophilia a with factor viii alloantibodies. its product candidate pipeline also include musk-caart, a preclinical stage product to treat a subset of patients with myasthenia gravis; fviii-caart, a discovery stage product to treat a subset of patients with hemophilia a; and dsg3/1-caart, a discovery stage product for the treatment of mucocutaneous pemphigus vulgaris. cabaletta bio, inc. has a collaboration with the un

Cabaletta Bio Inc executives and stock owners

Cabaletta Bio Inc executives and other stock owners filed with the SEC include:

• Anup Marda,
  Chief Financial Officer
• Steven Nichtberger,
  Chairman of the Board, President, Chief Executive Officer, Co-Founder
• Gwendolyn Binder-Scholl,
  Executive Vice President, Science & Technology
• Dr. Steven A. Nichtberger M.D.,
  Co-Founder, Chairman, CEO & Pres
• Dr. Steven A. Nichtberger,
  Co-Founder, Chairman, CEO & Pres
• Dr. David J. Chang M.D., M.P.H.,
  Chief Medical Officer
• Dr. Gwendolyn K. Binder,
  Exec. VP of Science & Technology
• Richard Henriques,
  Independent Director
• Catherine Bollard,
  Independent Director
• Mark Simon,
  Independent Director
• Brian Daniels,
  Independent Director
• David Chang,
  Chief Medical Officer
• J. Brian Stalter,
  General Counsel
• Michael Gerard J.D.,
  Gen. Counsel & Sec.
• Heather Harte-Hall M.Sc.,
  Chief Compliance Officer
• Michael Gerard,
  Gen. Counsel
• Dr. Samik Basu M.D.,
  Chief Scientific Officer
• Martha O'Connor,
  Chief HR Officer
• J. Brian Stalter J.D.,
  Gen. Counsel
• Dr. Aimee Payne M.D., Ph.D.,
  Co-Founder & Co-Chair of Scientific Advisory Board
• Dr. Michael C. Milone M.D., Ph.D.,
  Co-Founder & Co-Chair of Scientific Advisory Board
• Anup Marda M.B.A.,
  Chief Financial Officer
• Shawn Tomasello,
  
• Scott C. Brun,
  
• Gwendolyn Binder,
  See Remarks
• Arun Das,
  Chief Business Officer
• Group, Llc Green Jeremy Red...,
  
• James E Deerfield Mgmt Iv, ...,
  
• Ventures V, L.P.5 Am Opport...,
  
• Michael Gerard,
  General Counsel